Amphastar Pharmaceuticals Revenue 2012-2024 | AMPH

Amphastar Pharmaceuticals revenue from 2012 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Amphastar Pharmaceuticals Annual Revenue
(Millions of US $)
2023 $644
2022 $499
2021 $438
2020 $350
2019 $322
2018 $295
2017 $240
2016 $255
2015 $252
2014 $210
2013 $230
2012 $204
2011 $118
2009 $84
Amphastar Pharmaceuticals Quarterly Revenue
(Millions of US $)
2024-06-30 $182
2024-03-31 $172
2023-12-31 $178
2023-09-30 $181
2023-06-30 $146
2023-03-31 $140
2022-12-31 $135
2022-09-30 $120
2022-06-30 $123
2022-03-31 $120
2021-12-31 $121
2021-09-30 $112
2021-06-30 $102
2021-03-31 $103
2020-12-31 $96
2020-09-30 $83
2020-06-30 $86
2020-03-31 $85
2019-12-31 $83
2019-09-30 $80
2019-06-30 $79
2019-03-31 $80
2018-12-31 $90
2018-09-30 $76
2018-06-30 $71
2018-03-31 $58
2017-12-31 $60
2017-09-30 $58
2017-06-30 $65
2017-03-31 $57
2016-12-31 $64
2016-09-30 $64
2016-06-30 $68
2016-03-31 $59
2015-12-31 $77
2015-09-30 $64
2015-06-30 $54
2015-03-31 $57
2014-12-31 $56
2014-09-30 $60
2014-06-30 $49
2014-03-31 $46
2013-12-31 $55
2013-09-30 $59
2013-06-30 $63
2013-03-31 $53
2012-12-31 $52
2012-09-30 $57
2012-06-30 $49
2012-03-31 $46
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.469B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00